Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from a Phase 2 OASIS trial for etrasimod to treat ulcerative colitis. Shares of the biopharmaceutical leaped $8.86 to close at $39.75.
Arena Pharmaceuticals reports positive study results
March 20, 2018 at 17:16 PM EDT
